NCT06773923 (OSTEOPRINT) is a Phase 3 clinical trial of PCL Scaffold in Bone Loss, sponsored by Universidad Austral de Chile.

Who is sponsoring NCT06773923?

NCT06773923 is sponsored by Universidad Austral de Chile.

What drugs are being tested in NCT06773923?

Interventions in NCT06773923: PCL Scaffold, PTFE + Bio-Oss®.

What condition does NCT06773923 study?

NCT06773923 studies Bone Loss, Jaw, Edentulous, Edentulous Mouth, Jaw Fractures, Bone Loss, Age Related.

Is NCT06773923 still recruiting?

NCT06773923 is currently enrolling by invitation. Last updated 15 January 2025.

Last reviewed 2025-01-15 · How we verify

NCT06773923: OSTEOPRINT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of 3D-printed Patient-specific Resorbable Scaffolds for Maxillary Bone Regeneration

ENROLLING BY INVITATION Phase 3 Last updated 15 January 2025

What this trial tests

Phase 3 trial testing PCL Scaffold in Bone Loss in 10 participants. Enrolling by invitation.

Timeline

1 July 2024

Primary endpoint
1 March 2025

1 December 2025

Quick facts

Lead sponsor	Universidad Austral de Chile
Phase	Phase 3
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	1 July 2024
Primary completion	1 March 2025
Estimated completion	1 December 2025
Sites	1 location across Chile

Drugs / interventions tested

PCL Scaffold
PTFE + Bio-Oss®

Conditions studied

Bone Loss — all drugs for Bone Loss →
Jaw, Edentulous — all drugs for Jaw, Edentulous →
Edentulous Mouth — all drugs for Edentulous Mouth →
Jaw Fractures — all drugs for Jaw Fractures →

Sponsor

Universidad Austral de Chile — full company profile →

Who can join

Adults 30 to 70, any sex, with Bone Loss or Jaw, Edentulous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to test the bone formation capacity of a 3D printed scaffold with a plastic material called Polycaprolactone (PCL), compared to the use of synthetic bone grafts, for bone formation in the maxilla or mandible of elderly patients in the city of Valdivia between the years 2023-2024. The main beneficiaries will be patients, users of the public or private health system, who require bone regeneration. The intermediate beneficiaries are the health team: doctors specializing in surgery and orthopedics, dentists, maxillofacial surgeons, dedicated to bone reconstruction and regeneration. The innovation of this new material is based on the provision of a biocompatible plastic, easy to handle, for domestic 3D printing of bone matrices that can be grafted in areas requiring bone regeneration.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoscale Approaches to Oro-Dental Tissue Engineering: A Review of Strategies, Composites, and Translational Challenges.
Wang P, Ye Y, Mei K, Chen B, et al · · 2026 · PMID 41878129 · DOI 10.2147/ijn.s575296
Alveolar Ridge Preservation Using Three-Dimensional Root Replicas of Polycaprolactone: A Radiological and Histological Evaluation of a Case Report.
Aravena PC, Flores ME, Turones LC, Pavicic F, et al · · 2025 · PMID 40710883 · DOI 10.3390/reports8020092

Verify or expand the search:

Other recruiting trials for Bone Loss

Currently open trials in the same condition.

NCT07156110 — Prosthetic Modality and MBL · NA · recruiting
NCT07196943 — Prospective Outcomes of Guided Equator Overdentures · recruiting
NCT06629961 — Impact of Transepithelial Abutment Connection and Disconnection in Dental Implants · NA · recruiting
NCT06527664 — Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN) · recruiting
NCT04112992 — An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects · recruiting

Other Universidad Austral de Chile trials

Trials by the same sponsor.

NCT07231614 — Anesthetic Effectiveness of Lidocaine Versus Articaine in Dentistry · Phase 4 · not yet recruiting
NCT06704113 — Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients · Phase 4 · not yet recruiting
NCT06792864 — Effectiveness of 3D Bone Matrix in Cranioplasty · Phase 3 · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06773923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Austral de Chile
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing